Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies
Ημερομηνία
2016Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Background: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of the study was to assess the clinical utility of anti-CUZD1/anti-GP2 by novel cell-based indirect immunofluorescence (IIF) assays in CrD. Methods: A total of 212 CrD and 249 UC patients followed up at a London IBD centre were investigated to simultaneously detect PABs, anti-GP2 and anti-CUZD1 by IIF using primate pancreatic tissue, and HEK293 over-expressing CUZD1 or GP2. Results: Overall, 88 (41.5%) CrDs compared to 26 (10.4%) UCs (p<0.001) tested positive for IgA and/or IgG anti-GP2 and/or anti-CUZD1 antibodies, while ASCA were found in 67.5% CrDs versus 19.2% UCs (p<0.0001); ASCA and/or PAB (anti-GP2 or anti-CUZD1) were detected in 76% CrD versus 34% UC patients. IgG anti-GP2 antibodies were less prevalent in L2 phenotype (p=0.002) and more prevalent in patients with stricturing disease (p=0.0418), even when a higher cut-off (≥1000 RU) was used (p=0.0396). Also, anti-GP2 IgG positive CrD patients had younger age of disease onset. IgA and/or IgG ASCA and anti-GP2 IgG antibody positive CrDs had younger onset of disease (p<0.0001), were more likely to have both ileal and colonic disease (p<0.0001) and had more stricturing (p<0.0001) than seronegative patients. Clinical correlates were not found for anti-CUZD1 positivity. Conclusions: PAB testing increases ASCA's serological sensitivity for CrD. Anti-GP2 detection, in isolation or in combination with ASCA, stratify CrD patients who phenotypically are characterised by a much younger onset of disease, extensive and stricturing behaviour. © 2016 by De Gruyter 2016.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases
Farkona S., Soosaipillai A., Filippou P., Liaskos C., Bogdanos D.P., Diamandis E.P., Blasutig I.M. (2017)Pancreatic autoantibodies (PABs) are detected in patients with inflammatory bowel disease (IBD). Their prevalence is higher in Crohn's disease (CrD) than in ulcerative colitis (UC). Glycoprotein 2 (GP2) and, more recently, ... -
(2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease
Manolakis A.C., Christodoulidis G., Kapsoritakis A.N., Georgoulias P., Tiaka E.K., Oikonomou K., Valotassiou V.J., Potamianos S.P. (2017)AIM: To investigate the impact of inflammatory bowel disease (IBD) on α2-Heremans-Schmid Glycoprotein (AHSG/fetuin A) and potential associations with disease and patient characteristics. METHODS: AHSG serum levels were ... -
PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis
Liu, H.; Norman, G. L.; Shums, Z.; Worman, H. J.; Krawitt, E. L.; Bizzaro, N.; Vergani, D.; Bogdanos, D. P.; Dalekos, G. N.; Milkiewicz, P.; Czaja, A. J.; Heathcote, E. J.; Hirschfield, G. M.; Tan, E. M.; Miyachi, K.; Bignotto, M.; Battezzati, P. M.; Lleo, A.; Leung, P. S.; Podda, M.; Gershwin, M. E.; Invernizzi, P. (2010)A dual isotype (IgG, IgA) enzyme-linked immunosorbent assay (ELISA) designed to provide enhanced detection of primary biliary cirrhosis (PBC)-specific autoantibodies against both major mitochondrial and nuclear antigens ...